Real-world study in analysis of effects on concomitant medications with parenterally administered shenmai for coronary heart disease.
- Author:
Jun-Jie JIANG
1
,
2
;
Hao TANG
3
;
Yan-Ming XIE
4
;
Hu YANG
3
;
Yan ZHUANG
5
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. studentjiangjunjie@
2. com
3. Renmin University of China, Beijing 100872, China.
4. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
5. The PLA Navy General Hospital, Beijing 100048, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Aspirin;
therapeutic use;
Coronary Disease;
drug therapy;
Drug Combinations;
Drug Therapy, Combination;
Drugs, Chinese Herbal;
administration & dosage;
Female;
Hospital Information Systems;
statistics & numerical data;
Humans;
Infusions, Parenteral;
Logistic Models;
Male;
Middle Aged;
Outcome Assessment (Health Care);
Pragmatic Clinical Trials as Topic;
Ticlopidine;
analogs & derivatives;
therapeutic use;
Treatment Outcome;
Young Adult
- From:
China Journal of Chinese Materia Medica
2013;38(18):3137-3140
- CountryChina
- Language:Chinese
-
Abstract:
In order to understand the treatment of coronary heart disease with parenterally administered Shenmai and the efficacy of combination therapies, the study selected 18 hospitals for analysis. Data from each hospital's hospital injection system (HIS) was collected. Data of in-patients receiving parenterally administered Shenmai for a diagnosis of coronary heart disease was analyzed using; the Apriori algorithm to model use, Clementine 12.0 linkage analysis to find correlations between various drugs, and chi-square test for commonly used combination therapies to ascertain the cure rate. In 5 583 patients with coronary heart disease, it was found that Shenmai was commonly used with isosorbide mononitrate, aspirin, clopidogrel hydrogen and common combinations of combination therapy, and that the cure rate was better in these combinations than for other treatment regimes. When Shenmai is used with combination therapies for coronary heart disease, treatment guidelines should be complied with. In clinical application, the types of concomitant medications and their interactions, should be observed so as to prevent of adverse reactions.
